FDA mulls advisory committee overhaul
This article was originally published in The Gray Sheet
Executive Summary
"I think it is time to quietly put together a wholesale review" of the advisory committee program, Acting FDA Commissioner Lester Crawford tells Medical Device Manufacturers Association annual meeting June 10 in response to membership concerns about the utility of drug and device panels. "This isn't the first time I have thought about [looking at the process]," Crawford said, noting that the idea has assumed greater significance with recent panel overrules by FDA in all five regulated product areas. HHS leadership has expressed concern with the number of experts becoming ensconced on panels after serving multiple terms, he said...
You may also be interested in...
Abbott's ‘Bedrock Of Good Health’ Nutritionals Business Faces Mounting Infant Formula Litigation
Nutritional product business had 5.1% Q1 sales growth and is like Abbott’s other segments, “super well-aligned to the global demographics and trends in health care,” says CEO Ford. But as it defends complaints of damages from powder formulas made at facility found with unsafe levels of bacterial contaminants, Abbott’s also targeted in litigation alleging failure to warn about risk of infants born prematurely developing necrotizing enterocolitis if fed cow’s milk-based formula.
‘Core Pillars’ Of Safety And Innovation Take Center Stage In FDA Reports
The US FDA has issued a pair of reports focused on device safety and innovation. The reports describe recent steps the agency has taken to improve in the two areas, and what it plans to do next.
Lilly Can Rest Easy As Tirzepatide Scores Phase III Sleep Apnea Win
Topline results from two studies in obstructive sleep apnea among obese adults showed efficacy crossing the 50% threshold that physicians have called clinically meaningful.